Akiram Therapeutics to Showcase Key Data on AKIR001 at Targeted Radiopharmaceuticals Summit Europe 2024
Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, will present breakthrough IND-enabling preclinical data on its drug candidate 177Lu-AKIR001 and the design of its first-in-human clinical trial at the Targeted Radiopharmaceuticals Summit Europe 2024 in Amsterdam, December 3-5. The data highlights the strong therapeutic potential of 177Lu-AKIR001, with first patient enrollment anticipated in early 2025.
The presentation will be delivered by Dr. Marika Nestor, CEO of Akiram Therapeutics and Professor of Biomedical Radiation Sciences at Uppsala University during the Preclinical & Translational Track of the summit. Her talk will highlight the strong therapeutic efficacy of 177Lu-AKIR001, Akiram’s proprietary drug candidate targeting CD44v6, a cancer marker linked to aggressive tumor growth. The drug has demonstrated promising results in preclinical tumor models. Key findings include toxicology studies and successful GMP labeling, which are part of the IND-enabling data (Investigational New Drug), further supporting the initiation of the first-in-human trial for 177Lu-AKIR001 in Q1 2025.
The presentation will also address strategic considerations for designing effective clinical trials, focusing on the transition from preclinical research to clinical trials and emphasizing the role of targeted radiopharmaceuticals in addressing significant unmet needs in oncology.
Presentation Details:
Title: From Innovation to Implementation: Preclinical Development & Clinical Trial Design for 177Lu-AKIR001
Date & Time: December 4, 2:15 PM
Session: Preclinical & Translational Track
Speaker: Marika Nestor
“Presenting at the TRP Summit is an exciting opportunity to share the progress of 177Lu-AKIR001 with the international radiopharmaceutical community,” says Prof. Marika Nestor, CEO of Akiram Therapeutics. “The therapy holds the potential to become a first-in-class treatment for multiple cancer types, including anaplastic and iodine-refractory thyroid cancer, head and neck squamous cell carcinoma, and non-small cell lung cancer. With clinical trials set to begin at Karolinska University Hospital in Sweden in early 2025, we are thrilled to contribute to discussions shaping the future of targeted cancer therapies.”
TRP – Targeted Radiopharmaceuticals Summit Europe 2024
The 6th annual Targeted Radiopharmaceuticals Summit Europe is a premier industry-focused event that brings together global leaders to discuss innovations, strategies, and clinical advancements in radiopharmaceuticals. Serving as a hub for networking and knowledge exchange, the summit attracts both industry pioneers and leading academic experts. For more information, visit the event website.
About Akiram’s Drug Candidate
Developed through antibody phage display and affinity maturation targeting the CD44v6 cancer marker, 177Lu-AKIR001 combines the radiation component lutetium-177 with a cancer-targeting molecule. Preclinical studies have demonstrated its potential as a first-in-class radiopharmaceutical therapy for cancers with high CD44v6 expression.
For more information, please contact:
Marika Nestor, CEO
Email: marika.nestor@akiramtherapeutics.com
About Akiram Therapeutics
Akiram Therapeutics is a Swedish biotech company focused on the development of targeted radioimmunotherapy for cancer, which is based on a proprietary antibody targeting the cancer marker CD44v6 combined with a radiation component. The therapy has generated strong preclinical results in cancer models in conditions that currently lack effective treatments. With the potential for its drug candidate to be classified as an orphan drug and recognized as first-in-class, the company is dedicated to advancing research in this field, including indications in head and neck cancer, lung cancer, and aggressive thyroid cancer. Headquartered in Uppsala, Sweden, Akiram Therapeutics is staffed with experts in radiation science research, cancer precision medicine, and drug development. To learn more, please visit Akiram’s website and follow Akiram on LinkedIn.
Tags:
